0000000000051994

AUTHOR

S. Calabuig Fariñas

Exosomes in NSCLC: Analysis of its cargo as a source of biomarkers

research product

Carcinoma of unknown origin: Deep genomic profile helps to achieve an accurate diagnosis

research product

Clinical impact of using a deep genomic profile in carcinoma of unknown origin

research product

CD5 and CD6: Evaluation of their role as prognostic biomarkers in resectable non-small cell lung cancer

research product

An expression signature characterizes cancer stem cells from lung adenocarcinoma patients

research product

Analysis of immunoregulatory biomarkers in early stages of non-small cell lung cancer

research product

Applicability of ctDNA at diagnosis and during the monitoring of EGFR-mutated patients

research product

Lung tumorspheres as a drug screening platform against cancer stem cells.

Treatment resistance and metastasis are linked to cancer stem cells (CSCs). This population represents a promising target, but remains unexplored in lung cancer. The main objective of this study was to characterize lung CSCs and discover new therapeutic strategies.

research product

Stemness characterization of tumorspheres from non-small cell lung cancer: Differential expression in CSC-related markers and signaling pathways

research product

Interactions of cancer stem cell and immune microenvironment in non-small cell lung cancer (NSCLC)

research product

Analysis of gut microbiota in advanced non-small cell lung cancer (NSCLC) patients treated with immune-checkpoints blockers

Abstract Background The microbiota community is considered as an organ of the human body. Recent studies have found that dysbiosis may have an impact on the interaction between immune regulation and tumor treatment. The main objective of this study is to characterize the gut microbiota in patients with non-small cell lung cancer (NSCLC) in advanced stages, and its relationship with obesity, smoking habits, clinical pathological features and response to treatment with immune-checkpoints blockers (ICB). Methods 16S rRNA gene sequencing was performed on 48 stool samples from advanced NSCLC patients prior to treatment with ICB (PD-1 inhibitor and PD-L1 inhibitor). The database used for the taxo…

research product

Prognostic Impact of Vegfa in Resectable Non-Small-Cell Lung Cancer

ABSTRACT Aim: Angiogenesis is a main process which happens in tumors and that promotes its growth, invasive capacity and metastasis. Host genetic variability within VEGF pathway may affect angiogenic signaling and alter patient's sensitivity to anti-angiogenic therapies and therefore the prognostic. The goal in the present study is to analyze the prognostic value of several SNPs in angiogenic genes and the relative expression of those genes, using a cohort of patients diagnosed with resectable non-small cell lung cancer. Methods: This study included 127 resectable (I-IIIA) NSCLC patients. RNA and DNA extractions from tissues were performed using Trizol®. 20 ng of DNA were used for studies o…

research product